Dr. Langer Discusses Ongoing Clinical Trials for Patients With Non-Driver NSCLC

Publication
Video
Evolving ParadigmsNon-Small Cell Lung Cancer
Volume 1
Issue 1

Corey J. Langer, MD, Perelman Center for Advanced Medicine; Hospital of the University of Pennsylvania, discusses ongoing clinical trials for patients with non-driver non-small cell lung cancer (NSCLC).

Articles in this issue
Dr. Langer Discusses the Prevalence of Patients With Non-Driver NSCLC
Dr. Langer Discusses the Prevalence of Patients With Non-Driver NSCLC
Dr. Langer Discusses Current Treatment Strategies for Patients With Non-Driver Nonsquamous NSCLC
Dr. Langer Discusses Current Treatment Strategies for Patients With Non-Driver Nonsquamous NSCLC
Dr. Langer Discusses Ongoing Clinical Trials for Patients With Non-Driver NSCLC
Dr. Langer Discusses Ongoing Clinical Trials for Patients With Non-Driver NSCLC
Dr. Langer Discusses Remaining Challenges With the Non-Driver NSCLC Population
Dr. Langer Discusses Remaining Challenges With the Non-Driver NSCLC Population
Nonbiomarker, Nonsquamous NSCLC: Diagnosis, Statistics, Staging, and Testing
Nonbiomarker, Nonsquamous NSCLC: Diagnosis, Statistics, Staging, and Testing
Current Treatment Strategies in Nonbiomarker Nonsquamous NSCLC
Current Treatment Strategies in Nonbiomarker Nonsquamous NSCLC
Emerging Treatment Strategies in Nonsquamous NSCLC
Emerging Treatment Strategies in Nonsquamous NSCLC
Nonbiomarker NSCLC Population a Challenging Obstacle, Expert Says
Nonbiomarker NSCLC Population a Challenging Obstacle, Expert Says
Dr. Bazhenova on the Prevalence of Patients With Non-Driver NSCLC
Dr. Bazhenova on the Prevalence of Patients With Non-Driver NSCLC
Dr. Bazhenova on Current Treatment Strategies for Patients With Nonsquamous NSCLC
Dr. Bazhenova on Current Treatment Strategies for Patients With Nonsquamous NSCLC
Dr. Bazhenova on Considering Factors to Treat Non-Driver Patients With NSCLC With Bevacizumab
Dr. Bazhenova on Considering Factors to Treat Non-Driver Patients With NSCLC With Bevacizumab
Dr. Bazhenova on Potential Impact of Immunotherapy in Non-Driver NSCLC
Dr. Bazhenova on Potential Impact of Immunotherapy in Non-Driver NSCLC
Dr. Bazhenova on Remaining Challenges and Future Treatment Landscape of Non-Driver NSCLC
Dr. Bazhenova on Remaining Challenges and Future Treatment Landscape of Non-Driver NSCLC
Dr. Bazhenova on the Treatment Landscape of Non-Driver NSCLC
Dr. Bazhenova on the Treatment Landscape of Non-Driver NSCLC
Therapeutic Options Developing for Nondriver NSCLC, But Challenges Remain
Therapeutic Options Developing for Nondriver NSCLC, But Challenges Remain

Newsletter

Stay up to date on practice-changing data in community practice.

Subscribe Now!
Recent Videos
Related Content
FDA Clears Oncomine Dx Express Test for Sunvozertinib in EGFR Exon 20+ NSCLC

FDA Clears Oncomine Dx Express Test for Sunvozertinib in EGFR Exon 20+ NSCLC

Jordyn Sava
July 7th 2025
Article

The FDA approves a rapid test for identifying patients with NSCLC eligible for sunvozertinib, enhancing timely, precision oncology care.

Read More

FDA Approval Marks Amivantamab's Milestone in EGFR+ NSCLC

FDA Approval Marks Amivantamab's Milestone in EGFR+ NSCLC

Jordyn Sava;Joshua K. Sabari, MD
March 15th 2024
Podcast

In this episode, Joshua K. Sabari, MD, discusses the FDA approval of amivantamab plus chemotherapy as a first-line treatment for patients with EGFR exon 20 insertion mutation-positive non-small cell lung cancer.

Listen

High-Dose Aumolertinib Shows Survival and Safety Profile in EGFR-Variant NSCLC

High-Dose Aumolertinib Shows Survival and Safety Profile in EGFR-Variant NSCLC

Tony Berberabe, MPH
July 2nd 2025
Article

Read More

Lisberg Discusses Dato-DXd's Role in Advanced Lung Cancer Care

Lisberg Discusses Dato-DXd's Role in Advanced Lung Cancer Care

Jordyn Sava;Aaron Lisberg, MD
December 15th 2023
Podcast

In this episode of Targeted Talks, Aaron Lisberg, MD, discusses results from the phase 3 TROPION-Lung01 study of datopotamab in advanced or metastatic non–small cell lung cancer.

Listen

TROP-2 Inhibitors Are Explored in Breast Cancer

TROP-2 Inhibitors Are Explored in Breast Cancer

Tony Berberabe, MPH
June 28th 2025
Article

Discover the latest advancements in breast cancer treatment at the 24th Annual International Congress, featuring expert insights and groundbreaking research.

Read More

Bladder-Sparing Approaches Gaining Ground in NMIBC

Bladder-Sparing Approaches Gaining Ground in NMIBC

Tony Berberabe, MPH
June 27th 2025
Article

Innovative treatments for non–muscle-invasive bladder cancer emerge, focusing on bladder preservation and improved outcomes with novel therapies and active surveillance strategies.

Read More